Latest Conference Articles

Tiragolumab-Atezolizumab Combo Shows Preliminary Clinical Activity in Metastatic Esophageal Cancer

Tiragolumab-Atezolizumab Combo Shows Preliminary Clinical Activity in Metastatic Esophageal Cancer

July 3rd 2021, 8:00pm

World GI Congress

The combination regimen was well tolerated with promising preliminary anti-tumor activity in patients with heavily pretreated esophageal cancer, who had not received immunotherapy.

Deep, Durable Responses Continue With Pembrolizumab and Trastuzumab in Gastric/GEJ Cancer

Deep, Durable Responses Continue With Pembrolizumab and Trastuzumab in Gastric/GEJ Cancer

July 3rd 2021, 6:00pm

World GI Congress

“We observed much more deeper responses and more meaningful responses [in the treatment arm] compared with the placebo arm, in which 15% of the population had deep responses of ≥ 80%."

Testing for Rare Genomic Alterations in Colorectal Cancer

Testing for Rare Genomic Alterations in Colorectal Cancer

July 2nd 2021, 5:04pm

World GI Congress

Michael J. Overman, MD, discusses the advances in testing for rare genomic alterations in colorectal cancer.

BRAF Mutant Allele Fraction May Be Prognostic Biomarker for Targeted Therapy Regimens for BRAF V600E+ mCRC

BRAF Mutant Allele Fraction May Be Prognostic Biomarker for Targeted Therapy Regimens for BRAF V600E+ mCRC

July 2nd 2021, 4:29pm

World GI Congress

A biomarker analysis utilized liquid biopsies to find potential prognostic and predictive biomarkers for patients with BRAF V600E–mutant metastatic colorectal cancer treated with BRAF, EGFR, and/or MEK inhibitors.

Paclitaxel and GSK2636771 Combo Shows Benefit in Certain Patients with Gastric Cancer

Paclitaxel and GSK2636771 Combo Shows Benefit in Certain Patients with Gastric Cancer

July 2nd 2021, 12:00pm

World GI Congress

The combination of paclitaxel and GSK2636771 showed encouraging antitumor activity and a manageable toxicity profile and in patients with PTEN-deficient advanced gastric cancer who progressed after first line chemotherapy.

Overall Survival Improved With 177 Lu-Dotatate for Patients With Progressive Midgut NETs

Overall Survival Improved With 177 Lu-Dotatate for Patients With Progressive Midgut NETs

July 2nd 2021, 10:00am

World GI Congress

Final overall survival and long-term safety results of the phase 3 NETTER-1 trial were presented during the World Congress on Gastrointestinal Cancer 2021.

Pooled Data Suggest Obese Patients With CRC May Benefit From Weight-Based Chemotherapy Doses

Pooled Data Suggest Obese Patients With CRC May Benefit From Weight-Based Chemotherapy Doses

July 2nd 2021, 6:00am

World GI Congress

Findings from the OCTOPUS Consortium of trial data have indicated that obese patients with colorectal cancer have a poorer survival from adjuvant chemotherapy treatment due to reduced treatment dose and average cumulative relative dose.

New Early-Onset Colon Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use

New Early-Onset Colon Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use

July 2nd 2021, 6:00am

World GI Congress

In a first-of-its-kind study, data reveal that unnecessary antibiotic use may increase the risk of colon cancer—especially in people under age 50. Findings were presented at the 2021 World Congress on Gastrointestinal Cancer.

Avapritinib Shows Promise in Chinese Patient Population With PDGFRA D842V-Mutant GIST

Avapritinib Shows Promise in Chinese Patient Population With PDGFRA D842V-Mutant GIST

July 1st 2021, 9:54pm

World GI Congress

Treatment with avapritinib in Chinese patients with PDGFRA D842V-mutant gastrointestinal stromal tumors revealed promising clinical benefit, according to a bridging study of the NAVIGATOR trial.

AP128 Vaccine Shows Preliminary Safety in Stage IV CRC

AP128 Vaccine Shows Preliminary Safety in Stage IV CRC

July 1st 2021, 8:56pm

World GI Congress

Scott Kopetz, MD, PhD, FACP, reviews the results of the phase 1b multicenter KISIMA-01 study, for which he presented preliminary results during the ESMO World Congress of Gastrointestinal Cancer 2021.